ArticleHeliyon2024

Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India.

Yuvaraj Krishnamoorthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.